MYD88 and renal carcinoma: The inhibition of NLRP3, as well as of the oligomerization of the myeloid differentiation primary response gene 88 (MyD88), reduces the cardiotoxicity and increases the anticancer properties of sunitinib, in renal cancer-bearing mice (60).